1
|
Thomas X, Heiblig M, Bozzoli V, Elhamri M. Decitabine for the treatment of adult patients (age ≥65 years) with newly diagnosed de novoor secondary acute myeloid leukemia. Int J Hematol Oncol 2013. [DOI: 10.2217/ijh.13.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
>SUMMARY Decitabine is a deoxynucleoside analogue of cytidine. Its use for the treatment of acute myeloid leukemia (AML) has been recently refined. It selectively inhibits DNA methyltransferases when administered at a dose of 20 mg/m2by a 1-h intravenous infusion for 5 consecutive days of a 4-week cycle in the AML study. This schedule has recently been approved by the EMA as a well-tolerated alternative treatment to cytarabine or supportive care in patients aged ≥65 years with de novo or secondary AML who are not candidates for intensive chemotherapy.
Collapse
Affiliation(s)
- Xavier Thomas
- Hospices Civils de Lyon, Lyon-Sud Hospital, Hematology Department, Pavillon Marcel Bérard, Bat.1G, 69495 Pierre-Bénite, France
| | - Mael Heiblig
- Hospices Civils de Lyon, Lyon-Sud Hospital, Hematology Department, Pavillon Marcel Bérard, Bat.1G, 69495 Pierre-Bénite, France
| | - Valentina Bozzoli
- Hospices Civils de Lyon, Lyon-Sud Hospital, Hematology Department, Pavillon Marcel Bérard, Bat.1G, 69495 Pierre-Bénite, France
| | - Mohamed Elhamri
- Hospices Civils de Lyon, Lyon-Sud Hospital, Hematology Department, Pavillon Marcel Bérard, Bat.1G, 69495 Pierre-Bénite, France
| |
Collapse
|